OM Pharma to unveil major real-world evidence breakthrough on Broncho-Vaxom at EAACI
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
The company will unveil preliminary findings showing that Broncho-Vaxom was associated with a 28–38% reduction in respiratory tract infection rates at 12 months
Subscribe To Our Newsletter & Stay Updated